Urethral cancer is one of the rarest cancers in the body, accounting for less than 1% of all malignancies, with an overall incidence of roughly 1.7 cases per million people per year in the United States.1PubMed Central. Incidence rates and contemporary trends in primary urethral cancer Because so few people develop it, large clinical trials are nearly impossible to run, and much of what doctors know comes from institutional case series, registry analyses, and collaborative databases. That scarcity of evidence makes the disease harder to study, harder to treat, and harder to discuss in broad strokes than almost any other cancer of the urinary tract.
How Common Is Urethral Cancer, and Who Gets It
Between 2004 and 2016, the U.S. SEER cancer registry recorded roughly 1,900 newly diagnosed primary urethral cancers, an age-adjusted rate of about 1.7 per million people.2PubMed Central. Incidence rates and contemporary trends in primary urethral cancer That rate did not change meaningfully over the study period. Men develop urethral cancer more often than women. One earlier SEER analysis put the annual incidence at roughly 4.3 per million in men and 1.5 per million in women, with the gap widest in the 75-to-84 age group, where rates peaked at about 32 per million men and 9.5 per million women.3PubMed. Incidence of primary urethral carcinoma in the United States That same analysis found African Americans had about twice the incidence of whites (roughly 5.0 vs. 2.5 per million).4PubMed. Incidence of primary urethral carcinoma in the United States
European data paint a broadly similar picture. A study spanning Poland, Latvia, Slovenia, and Hungary from 2000 to 2019 found that 94% of cases occurred in people over 45, with Hungary showing the highest rates and Poland the lowest.5PubMed Central. Epidemiology of Primary Urethral Cancer: Insights from Four European Countries with a Focus on Poland In Poland specifically, men and women were affected in nearly equal numbers, a contrast with the stronger male predominance seen in American data. The reasons for these geographic and racial differences are not well understood, but they likely reflect some combination of genetic susceptibility, rates of human papillomavirus (HPV) infection, and differences in how urethral cancers are classified in different registries.
Risk Factors
Because the disease is so rare, pinning down risk factors has been difficult. The clearest associations involve chronic irritation or infection of the urethral lining. Conditions like urethral strictures, chronic urinary tract infections, and sexually transmitted infections create long-standing inflammation, which over time can promote abnormal cell growth. HPV, the same virus implicated in cervical and oropharyngeal cancers, has been documented in about a third of urethral tumors in one pathology series.6PubMed Central. Carcinoma of the urethra That finding carries practical significance: it suggests urethral cancer is not a single disease but at least two biologically distinct entities, one driven by HPV and one that arises through other pathways.
In women, urethral diverticula, which are small outpouchings of the urethral wall, represent an additional risk. A study of 90 women with urethral diverticula found neoplastic changes in about 6% of them, all of glandular origin, including clear-cell and invasive adenocarcinomas.7PubMed. Urethral diverticula in 90 female patients: a study with emphasis on neoplastic alterations Some of those patients also showed precancerous tissue changes like intestinal metaplasia and high-grade dysplasia. Whether routine screening of women with known diverticula could catch cancers early is an open question; the numbers are simply too small for anyone to have studied it in a controlled way.
Histological Types Differ Between Men and Women
Urethral cancer is not one disease under a microscope. The cell type that predominates depends on where the tumor arises in the urethra and on the patient’s sex. In men, the most common form is urothelial carcinoma (the same cell type that causes most bladder cancers), making up about 47% of cases. Squamous cell carcinoma accounts for roughly 30%, and adenocarcinoma for about 11%.8The French Journal of Urology. Primary urethral carcinoma: Recommendations of the oncology committee of the French Urology Association In women, the pattern flips: adenocarcinoma, particularly clear-cell and intestinal subtypes, is the most frequently observed histology.9The French Journal of Urology. Primary urethral carcinoma: Recommendations of the oncology committee of the French Urology Association
This sex-based difference matters for treatment planning. Urothelial carcinoma responds to the same chemotherapy regimens used for bladder cancer, while squamous cell carcinoma may be more amenable to radiation-based approaches. Adenocarcinomas, being rarer and biologically distinct, have fewer established treatment protocols. The clear-cell subtype in women is especially uncommon and most cases originate from urethral diverticula.10PubMed Central. Primary clear cell adenocarcinoma of female urinary tract: a case report and literature review Some pathologists believe clear-cell adenocarcinoma of the urethra may share a developmental origin with certain kidney-related tissues, based on its immunohistochemical profile.11PubMed. Histology and immunohistochemistry of clear cell adenocarcinoma of the urethra: histogenesis and diagnostic problems
Symptoms and Diagnosis
Early urethral cancer often produces symptoms that overlap with far more common conditions. Blood in the urine, difficulty urinating, a palpable mass near the urethra, or a discharge that does not respond to antibiotics are the most typical presenting complaints. In women, a visible or palpable lesion at the urethral opening may be the first sign. In men, symptoms can mimic a urethral stricture or chronic prostatitis, which means the cancer sometimes goes undiagnosed for months while the patient is treated for something else.
When urethral cancer is suspected, MRI is the preferred imaging study because it provides the best detail of the soft tissues surrounding the urethra and can show how deeply a tumor has invaded local structures.12Indian Journal of Medical and Paediatric Oncology. Imaging Recommendations for Diagnosis, Staging, and Management of Bladder and Urethral Malignancies A biopsy through a cystoscope confirms the diagnosis and establishes the histological type. CT scans of the chest, abdomen, and pelvis are typically added to check for spread to lymph nodes or distant organs.
What Drives Prognosis
The outlook for urethral cancer depends heavily on how advanced the disease is at diagnosis, and a troubling proportion of patients present late. Registry data suggest that while T1 (early-stage) tumors remain the most common single category, their incidence has been declining slightly, while the proportion of locally advanced cases with lymph node involvement has been rising. Institutional series paint an even starker picture, with some centers reporting that over half their patients have locally advanced disease by the time they are seen.
In a large analysis of prognostic factors in men, older age, higher tumor grade, deeper local invasion, and the presence of lymph-node or distant metastases all predicted worse survival.13PubMed. Prognostic factors in male urethral cancer Interestingly, adenocarcinoma carried a somewhat better prognosis than urothelial carcinoma in that analysis, and patients who underwent radical surgery fared better than those who did not. A separate international collaborative study confirmed that clinical nodal stage was the single most important independent predictor of both recurrence-free and overall survival.14PubMed Central. Prognostic factors and outcomes in primary urethral cancer: results from the international collaboration on primary urethral carcinoma Tumor location within the urethra and patient age also mattered, but nodal status dominated the analysis. The practical implication: whether cancer has reached the lymph nodes is the most critical piece of information a patient and their doctor need when discussing treatment options.
Surgery and the Shift Toward Organ Preservation
Historically, the surgical approach to urethral cancer was aggressive. For proximal tumors in men, treatment meant removing the entire penis along with the bladder and prostate. For distal tumors, partial or radical penectomy was the standard, with a goal of achieving a two-centimeter margin of cancer-free tissue.15PubMed Central. Organ-preserving surgery for male distal primary urethral carcinoma: A case report from a tertiary hospital in Ethiopia These operations are effective at removing cancer but carry profound consequences for urinary and sexual function.
Over the past two decades, there has been growing interest in organ-sparing approaches for carefully selected patients. In women with small distal tumors, transurethral resection and laser ablation have been tried, though local failure rates of around 16% and relatively modest long-term survival mean these approaches are best reserved for low-stage disease.16Annals of Urology & Nephrology. Review on Organ Preserving Techniques in Patients with Urethral Carcinoma Partial urethrectomy has been more widely used; in one long-term series of 27 women who underwent partial removal for early-to-moderately advanced tumors, about 22% developed a local recurrence.17Annals of Urology & Nephrology. Review on Organ Preserving Techniques in Patients with Urethral Carcinoma Among those who recurred, the five-year post-recurrence mortality was high, at 71%, underscoring that even when organ preservation is attempted, close follow-up is essential.
Bladder-sparing surgery has also been explored for selected women with locally advanced urethral cancer. A small series of five women treated with wide local excision, with or without concurrent radiation, achieved local control in all patients over follow-up periods of up to about six years.18PubMed. Bladder sparing surgery for locally advanced female urethral cancer Numbers that small cannot be generalized, but they suggest that for the right patient, preserving the bladder is possible without sacrificing cancer control.
Chemoradiation as an Alternative to Radical Surgery
For locally advanced urethral cancer, combining chemotherapy with radiation has emerged as a viable alternative to mutilating surgery. The rationale is borrowed from the treatment of anal and vulvar squamous cell cancers, where chemoradiation can cure the disease while preserving the organ. In urethral cancer, this approach offers the possibility of avoiding penectomy in men or extensive pelvic surgery in women.19PubMed Central. Radiotherapy for Primary Urethral Carcinoma (PUC): An Illustrative and Narrative Review
The largest published experience with combined chemoradiation for invasive male urethral cancer reported that about 79% of patients achieved a complete response. Of those complete responders, however, 42% eventually relapsed at a median of roughly a year. Five-year overall survival was 52%, and disease-specific survival was about 68%.20PubMed. Combined chemoradiation as primary treatment for invasive male urethral cancer The 21% of patients who did not respond to treatment ultimately died of their disease despite salvage efforts. These numbers illustrate the tension at the heart of urethral cancer treatment: chemoradiation can spare organs and still cure a majority of patients, but when it fails, the outcomes are grim. Choosing between upfront radical surgery and chemoradiation requires a candid conversation about the patient’s priorities, the tumor’s biology, and how well the tumor is likely to respond.
Immunotherapy and Genomic Targets
Because urethral cancer is so rare, no immunotherapy drug has been approved specifically for it. In practice, doctors often borrow from treatment paradigms for bladder cancer or other squamous cell cancers. Checkpoint inhibitors, which block proteins that prevent the immune system from attacking cancer cells, have shown anecdotal promise. One published case of metastatic squamous cell urethral cancer described a complete radiological response of liver and lymph node metastases after just four cycles of pembrolizumab, an anti-PD-1 drug.21PubMed Central. A Rare Case of Metastatic Urethral Squamous Cell Carcinoma Presenting with Paraneoplastic Sweet Syndrome and Treated with Pembrolizumab A single case report cannot establish a treatment standard, but it does suggest that at least some urethral cancers are immunologically responsive.
Genomic profiling has started to map out potential drug targets. A study of 127 urethral cancers across all major histological subtypes found that mutations in the PIK3CA gene were the most frequent potentially targetable alteration. Mutations in PTEN, ERBB2, FGFR genes, BRAF, and MET were also identified at lower frequencies, varying by histological subtype. One notable finding was that microsatellite instability, a biomarker that predicts response to immunotherapy in many other cancers, was absent across all subtypes tested.22PubMed Central. A Rare Case of Metastatic Urethral Squamous Cell Carcinoma Presenting with Paraneoplastic Sweet Syndrome and Treated with Pembrolizumab The absence of microsatellite instability is a bit surprising given that checkpoint inhibitors have shown activity in individual cases. It may mean the responses seen with immunotherapy are driven by other factors, such as high tumor mutational burden or PD-L1 expression, rather than by the mismatch repair defects that drive microsatellite instability.
Primary Urethral Melanoma
Among the rarest forms of an already rare cancer is primary melanoma of the urethra. Unlike the melanomas that develop on sun-exposed skin, urethral melanomas arise from melanocytes that reside in the mucosal lining of the urethra. They can occur in both sexes, though the handful of published cases skew toward women. A report of a female patient described a polypoid and nodular melanoma at the squamous-urothelial junction with lymphovascular invasion but no BRAF gene mutation, which is the actionable target in many cutaneous melanomas.23PubMed Central. Primary malignant melanoma of the female urethra: A case report A male case described a melanoma of the penile urethra with a similarly unusual molecular profile and extensive local invasion into the surrounding erectile tissue.24Journal of Clinical and Translational Pathology. Primary Mucosal Melanoma of the Penile Urethra: A Case Report of an Extremely Rare Disease with a Unique Molecular Profile
These mucosal melanomas are clinically important because they behave differently from their skin-based counterparts. They tend to be diagnosed at a more advanced stage, and the absence of common melanoma driver mutations like BRAF V600E means that the targeted therapies widely used for cutaneous melanoma often do not apply. Treatment typically involves surgical excision with wide margins, and the prognosis is generally poor because of the tendency for late diagnosis and early spread.
Monitoring After Treatment With Circulating Tumor DNA
Follow-up after treatment for urethral cancer has traditionally relied on physical examination, cystourethroscopy, and periodic imaging. All of these methods have limitations: imaging may not detect microscopic disease, and physical exams are inherently imprecise. A newer approach under investigation uses circulating tumor DNA (ctDNA), which are fragments of tumor genetic material shed into the bloodstream. By looking for DNA mutations specific to the patient’s tumor, clinicians can potentially detect recurrence earlier than imaging alone would allow.
An early study testing tumor-informed ctDNA monitoring in patients with locally advanced penile and urethral cancers found that ctDNA results agreed with imaging findings at nearly 99% of time points assessed, with testing performed roughly every three to four months.25PubMed. Utility of Tumor-Informed Circulating Tumor DNA for Monitoring Treatment Response in Nonmetastatic, Locally Advanced Penile and Primary Urethral Cancers While the study was small and confirmatory trials are needed, the concordance rate is encouraging. If ctDNA testing proves reliable in larger groups, it could supplement or partially replace the imaging-heavy surveillance protocols currently used, giving patients and doctors a faster, less invasive way to catch recurrences before they become visible on a scan.
Why Urethral Cancer Remains Understudied
The fundamental challenge with urethral cancer is that its rarity makes it nearly invisible in the oncology research landscape. With fewer than 2,000 cases over a dozen years in the entire U.S. registry, randomized controlled trials of the sort that have transformed treatment for breast, lung, or even bladder cancer are practically impossible. Most treatment protocols are extrapolated from better-studied cancers that share a histological type: urothelial urethral cancer is treated like bladder cancer, squamous urethral cancer borrows from cervical or anal cancer protocols, and adenocarcinoma is treated on an ad hoc basis. Whether those borrowed regimens are optimal for a tumor in the urethra, with its unique anatomy, blood supply, and patterns of spread, remains genuinely unknown.
International collaborations have helped fill some gaps. Pooling data across institutions in different countries has allowed researchers to identify prognostic factors and compare outcomes across treatment strategies, even if the total patient numbers remain modest.26PubMed Central. Prognostic factors and outcomes in primary urethral cancer: results from the international collaboration on primary urethral carcinoma Genomic profiling is starting to reveal actionable mutations that could connect urethral cancer patients to basket trials, where drugs are tested across multiple cancer types that share the same molecular target. For now, though, a patient diagnosed with urethral cancer is best served at a center that sees enough cases to have institutional experience with the disease, because individual clinical judgment fills many of the gaps that evidence-based guidelines have not yet closed.